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We devised a diagnostic approach based on screening plasma for an Aspergillus antigen with 
use of a sandwich enzyme-linked immunosorbent assay (ELISA), thoracic computed tomographic 
scanning, and radionuclide imaging for managing patients at risk for invasive aspergillosis. We 
used a decision analytic model to compare this alternative strategy with the conventional strategy, 
which relies only on the presence of clinical symptoms, persistent fever, and chest roentgenographic 
findings. Use of the alternative strategy reduced the number of patients who would receive antifungal 
treatment empirically, but this strategy was more expensive. The specificity of the sandwich ELISA 
had a significant impact on cost, but the sensitivity did not. A 13% prevalence of infection resulted 
in equal costs for both strategies. As much as 43.3% of the patients treated empirically could be given 
liposomal amphotericin B (L-AmB) before the conventional strategy became the most expensive. The 
costs of the alternative strategy were less than those of the conventional strategy when >5.3% of 
all patients, irrespective of strategy, were treated with L-AmB.
Invasive pulmonary aspergillosis is a life-threatening com- tericin B colloid dispersion (Amphocil, Zeneca Farma, Rid-
plication of intensive chemotherapy for malignancies, chronic 
treatment with high dose corticosteroids, transplantation, and 
AIDS. Treating this infection as early as possible is one of the 
prerequisites for a favorable outcome [1], but since 110 reliable 
means of early diagnosis exists, it has become commonplace
derkerk, the Netherlands), are available and are being used 
increasingly for treating invasive aspergillosis because they 
induce fewer side effects than occur with the same dose of 
DC-AmB. Although equal or improved efficacy of lipid formu­
lations of amphotericin B in treating invasive aspergillosis has
to treat patients at high risk empirically with amphotericin not been proven, all the studies to date have shown that lipid
formulations of amphotericin B are at least as effective as 
DC-AmB, even in those patients who did not respond [5-7]. 
Moreover, clinical trials are ongoing to establish the efficacy 
alone [3, 4], even though the desoxycholate formulation of of lipid formulations of amphotericin B as empirical therapy for
B when there is the slightest clinical suspicion of invasive 
aspergillosis [2]. As many as 68% of neutropenic patients will 
receive amphotericin B empirically, often for persistent fever
amphotericin B (DC-AmB; Fungizone, Bristol Myers Squibb,
Woerden, the Netherlands) is associated with adverse drug 
reactions such as fever, rigors, and impaired renal function. In 
addition, the incidence of disease for most groups at risk is 
as 10%. Therefore, alternative strategies are needed for the early 
recognition of invasive aspergillosis to allow better selection 
of patients who need treatment, while reducing the number of who are intolerant of DC-AmB or for managing progressive
patients who are exposed unnecessarily to these drugs and their disease despite treatment with the desoxycholate formulation
of the polyene [5]. Even if desirable, empirical treatment with
In addition, better selection of patients who require treatment L-AmB is simply not feasible since resources for health care are 
for invasive aspergillosis will also help to contain the cost o f finite and there is increasing pressure to contain costs despite an
fever and neutropenia and as first-line therapy for documented 
aspergillosis [5].
However, the cost of treatment with these formulations is 
high. L-AmB is as much as 40 times more expensive than 
DC-AmB and is only considered for managing invasive asper­
gillosis in patients with impaired renal function or in those
treatment when novel and expensive drugs are used. For in­
stance, lipid formulations of amphotericin B, such as liposomal 
amphotericin B (L-AmB; Ambisome, Nexstar, St. Odilienberg, 
the Netherlands), amphotericin B lipid-complex (Abelcet, The 
Liposome Company, Reeuwijk, the Netherlands), and ampho-
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ical Mi-
inexorable rise in demand.
To address this issue we devised a diagnostic approach (alter­
native strategy) that incorporates Aspergillus antigen detection, 
high resolution CT scanning, and radionuclide imaging with 
indium-111-labeled human IgG ("'in-IgG). Each of these pro­
cedures have been shown to contribute to establishing the diag­
nosis o f invasive aspergillosis, but the diagnostic value o f  an 
approach in which the tests and procedures are combined is 
unknown. The Aspergillus antigen galactomannan can be de­
tected in plasma or serum samples from patients with invasive 
aspergillosis by using a commercially available sandwich 
ELISA (Platelia Aspergillus, Sanofi Diagnostics Pasteur, 
Marnes-La-Coquette, France) [8]. This assay has been found 
to possess a sensitivity of 67%-100%  and a specificity of
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Decision tree for two
strategies for the management of 
invasive aspergillosis. The squares 
in the decision tree i a deci­
sion node. If  one branch continues 
from a decision node, only one 
decision is possible. The nodes 
represented by circles are used if 
subsequent outcomes occur by 
chance. Theoretical outcomes of 
chance nodes with a zero probabil­
ity, such as no symptoms of asper­
gillosis after a 
ELISA, are not shown in the tree. 
The path probabilities (P) of each 
branch of the tree are shown. Un­
der baseline assumptions, the prob­
ability o f receiving 
treatment in the conventional strat­
egy (A), which is based on persis­
tent fever, bronchoalveolar lavage 
(BAL), and chest roentgenogram 
findings, is .24 (.06 +• .18). The 
probability o f  receiving antifungal 
treatment in the alternative strategy 
(B), based on screening plasma for 
an Aspergillus antigen by using a 
sandwich ELISA, thoracic CT 
scanning, and radionuclide im­
aging ( n 'In-labeled IgG) is .073 
(.054 + .005 +  .003 + .003 + .008 
+  .000).
each test result, together with the costs of the diagnostic tests 
and treatments, were estimated and incorporated into the deci­
sion tree by using the software program DATA version 2.6 
(TreeAge Software, Williamstown, MA). After the path proba-
additional costs of the diagnostic tests included in the alterna­
tive strategy were outweighed by any savings resulting from 
the avoidance of unnecessary treatment. Since different values 
for both sensitivity and specificity of the sandwich ELISA have
bilities of each branch of the tree and the expected costs of been reported [9-13], the impact of varying the performance
diagnosis and treatment per patient were calculated for each 
strategy, sensitivity analysis was performed.
Primary calculations on the costs of both strategies were 
based on treatment with DC-AmB to determine whether the
Table 1. Baseline values and ranges of variables and test character­
istics used to construct the decision tree for comparing two strategies 
for managing invasive aspergillosis.
Reference: Variable
Baseline 
value (%)
[PR]
f .....'......... ' n'"1BI" in " ' "
Prevalence o f invasive aspergillosis 6
1 i 0] ELISA sensitivity 100
[10] ELISA specificity 94
[H ] CT scan sensitivity 89
Set CT scan specificity 95
[17] IIJIn-labded IgG scintigraphy sensitivity 90
Set m In-labeled IgG scintigraphy specificity 90
[PR] Patients receiving empirical treatment with 
desoxycholato formulation o f  amphotericin B
24
NOTE. Set =  estimates o f performance characteristics.
characteristics of the sandwich ELISA on the positive and 
negative predictive values and the expected costs of the alterna­
tive strategy was determined by varying the sensitivity and 
specificity with use of values from the literature and the hypo­
thetical values of 50% and 99%, given a 6% prevalence rate 
of infection. Besides this, we used the variables prevalence of 
infection (baseline value, 6%), the probability that a patient 
would receive empirical treatment with DC-AmB (baseline 
value, 24%), and the costs of the sandwich ELISA (baseline 
value, $ 10) in the sensitivity analysis.
Treatment with L-AmB. The impact of the availability of 
L-AmB was evaluated by incorporating three different possibil­
ities of using this expensive drug in the model. First, we as­
sumed that all patients with invasive aspergillosis diagnosed 
by the alternative strategy would be treated with L-AmB and 
that all patients whose cases were diagnosed by the conven­
tional strategy would be treated with DC-AmB. Second, we 
analyzed the situation in which all patients with invasive asper­
gillosis diagnosed by the alternative strategy would be treated 
with L-AmB and that a varying proportion of those cases diag­
nosed by the conventional strategy would also be treated with
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Table 2. Costs o f diagnostic tests and procedures used in the two strategies for the management of
invasive asperg
Diagnostic procedure Specification
Costs per 
test ($)
No. of tests or 
procedures performed
Conventional strategy
Chest roentgenogram V  «  • 44 3
Bronchoalveolar lavage Includes cytology and bacteriologic, 
virological, and mycologicai cultures
562 1
Alternative strategy
■
Aspergillus antigen detection Sandwich ELISA 10 30"*
High-resolution CT scanning Lungs and sinuses 467 1
U!In-labeled IgG scintigraphy t  f « 555 1
* All patients are screened by sandwich ELISA during each neutropenic episode.
L-AmB. Last, we assumed that the same proportion o f  patients 
whose cases were diagnosed according to both strategies would 
receive L-AmB. In addition, for the second and third scenarios, 
we calculated the threshold at which the expected costs were 
equal for both strategies. We also performed a two-way sensi­
tivity analysis to examine the relationship between the propor-
mained high (table 3). Decreasing the specificity of the test 
from 99% to 50%) nearly doubled the
because the number of false-positive 
to the more frequent performance of CT scanning. By contrast, 
lowering the sensitivity of the ELISA from 99% to 50% had 
only a marginal effect on the expected costs per patient, reduc­
tion of patients treated with L-AmB and the prevalence of ing them from $480 per patient to $476 per patient when the
invasive aspergillosis.
Results
Probability o f receiving treatment. The probability o f re­
ceiving antifungal treatment as a result of the conventional 
strategy was .24 (figure 1; path probabilities, .06 + .18), while 
the probability of receiving antifungal treatment unnecessarily 
was .18. The probability of receiving antifungal treatment as 
a result of the alternative strategy was .073 (figure 1; path
.054 + .005 + .003 + .003 + .008 + .000), 
with 74% of these cases identified by antigen detection and 
confirmed by CT scanning. The probability of a patient incor­
rectly receiving treatment was .013, whereas only one of every 
1,000 patients would incorrectly not receive treatment as a 
result of a positive ELISA result unconfirmed by imaging. The 
expected costs of diagnosis by the conventional and alternative 
strategies were estimated respectively to be $167 per patient
and $463 per patient, res My, and those of treatment were
$156 per patient and $63 per patient, respectively. Thus, the
of $93 per patient, accrued byïs on t
did not compensate for the extra 
investment in the diagnostic tests and procedures ($296 per 
patient). Under baseline assumptions, an overall investment of 
$203 per patient would be required to implement the alternative 
strategy.
Test characteristics. As expected, the positive 
value for the conventional strategy was low (25%), and the 
negative predictive value was high (100%). Irrespective of the 
level of sensitivity, the positive predictive value o f  the alterna-
specificity was 99%, and from $922 per patient to $919 per 
patient when the specificity was 50%. This effect is due to the 
fact that patients with a false diagnosis of freedom from disease 
will ultimately develop clinical signs and symptoms consistent 
with invasive aspergillosis and will still undergo CT scanning.
Sensitivity analyses. When the baseline values for the sen-
*
sitivity and specificity o f the sandwich ELISA were used, the 
alternative strategy became less expensive than the conven­
tional strategy once the prevalence o f invasive aspergillosis 
exceeded 13% (figure 2), and even when the worst test perfor­
mance values were used, 
to 15,1%. Similarly, the 
a prevalence o f 11.5%
increased only slightly 
dropped only marginally to 
the best test performance values
of sensitivity and specificity of the sandwich ELISA
At a prevalence rate of 13%, the probability of patients having 
invasive aspergillosis but wrongly not receiving treatment re-
. Given baseline valuesmained at i 1
for the performance 3 alternative strategy,
strati'« more expensive than
that a patient would be treated
exceeded 48.8%.
were equal
costs per patient of the 
the cost of the sandwich ELISA
was $3.30.
Treatment with L- The expected costs of the alterna­
tive strategy were estimated to be $3,096 per patient, assuming 
that each patient invasive
tre This approach was always be more ex­
pensive than the conventional strategy and treatment with
not be identified for the prev-DC-AmB, since thresholds c
alence of infection, for the probability that a patient would 
tive strategy declined from 88% to 54% as the specificity o f  receive empirical treatment, or for the costs of the sandwich
the ELISA decreased, but the negative predictive value re- ELISA. was available to all patients,
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Table 3. Positive and negative predictive values and expected costs per patient of an alternative strategy for the management of invasive 
aspergillosis, calculated for varying values o f  the sensitivity and specificity of the sandwich ELISA.
Source o f  data
Sensitivity of 
ELISA (%)
Specificity of 
ELISA (%)
PPV of the 
strategy (%)
NPV of the 
strategy (%)
Total expected costs 
per patient ($)
Reference
[ 10] 100 94 81 99.9 525
112] 100 89 77 99.9 571
[9] 90 84 73 99.9 615
1 1 1 ] 67 94 81 99.8 523
Hypothetical values
99 99 88 99.9 480
99 50 54 99.9 922
50 99 88 99.9 476
50 50 54 99.7 919
NOTE. NPV =  negative predictive value; PPV
43.3% of the 24% of patients given empirical antifungal therapy reduced
i
14-fold from .18 to .013 by using the alternative
as a result of the conventional strategy could be treated with strategy we propose. We were also encouraged by the finding 
this formulation before the alternative strategy became less that the probability o f withholding treatment incorrectly was
expensive. Assuming that only a proportion of patients were 
treated with L-AmB, irrespective of the diagnostic strategy
likely to be very low (.001), although not zero. However, we 
assumed that no cases would go undiagnosed by the conven-
used, the one-way sensitivity analysis showed that the expected tional strategy, which is unlikely to be the case, since invasive
costs o f the alternative strategy were only lower than those of aspergillosis only becomes apparent at autopsy for the majority
the conventional strategy when >5.3%  of all patients given of patients [20].
antifungal therapy were treated with L-AmB. The two-way The strategy we propose requires physicians to withhold
sensitivity analysis (figure 3) showed an inverse relationship treatment from patients who would otherwise have received
between the proportion of patients treated with L-AmB therapy empirically. Typically, these patients would be febrile
for invasive aspergillosis and the prevalence of invasive asper- and neutropenic, but galactomannan would not be detected in
blood samples, and CT scans would not show lesions consistent 
with invasive aspergillosis. Of course, other fungal pathogens 
may cause clinical signs and symptoms that are difficult to 
differentiate from invasive aspergillosis; nevertheless, the fear 
The increasing incidence of invasive aspergillosis [20], the that patients may die o f invasive aspergillosis compels many
Discussion
high morbidity and mortality associated with the infection, and 
the costs o f treatment with novel antifungal agents underscore
to mammine tthe need for alternative 
The decision tree we constructed can be used as a model to 
predict the outcome and expected costs of implementing strate­
gies for diagnosing or treating invasive aspergillosis in patients
physicians to begin treatment empirically after 3 -5  days of 
persistent fever that is refractory to antibacterial therapy, even 
in the absence o f any pulmonary or sinus abnormalities. Thus, 
as many as two-thirds of all neutropenic patients are given 
empirical antifungal therapy [3, 4].
Clearly, the withholding of treatment will be difficult to achieve
?al treatment, rather than
with hematologic malignancies. We 
patients who would receive 
survival, as the measure of outcome since 
is more commonplace and usefu l, whereas the mortality associ­
ated with invasive aspergillosis depends not only on antifungal
treatment but also on whether remission from the underlying 
disease is achieved [ I ]. However, we acknowledge that the 
baseline values necessary for decision analysis are likely to
proportion of in such circumstances because the morbidity associated with DC
differ between different institutions and depend on the nature 
and type o f tests and procedures used to diagnose invasive 
aspergillosis, the prevalence of the disease, and, more im­
portant, the guidelines governing the institution of empirical 
antifungal therapy.
Under the assumed baseline values obtained at our hospital, 
the probability o f receiving treatment unnecessarily could be
AmB therapy is regarded as less harmful than is the withholding 
of treatment from a patient with disease. Furthermore, when other 
less toxic antifungal agents are made available, the threshold for 
treating patients empirically will be lower still, with only the high 
cost of novel antifungal agents and the finiteness of resources 
providing disincentives to using these drugs empirically. The eval­
uation of alternative strategies for managing invasive aspergillosis 
is therefore imperative if we are to define the place of new antifun­
gal agents and control their use.
The baseline values for the performance of the sandwich 
ELISA were based on the results of a prospective study of 
children during treatment for a hematologic malignancy [10]. 
However, false-positive ELISA results have been reported to 
occur within 30 days after bone marrow transplantation [11]
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of treatment with this formulation even though they were ex­
pected to be high because a larger number of cases diagnosed 
by the conventional strategy would receive treatment. As a 
consequence, all calculated expected costs were a conservative 
estimate of the actual costs. Nevertheless, the alternative strat­
egy we propose will become less expensive than the conven­
tional strategy if >5.3%  of the treated patients are treated with 
L-AmB and it will become even less expensive if  it proves
in circumstances where the majority of patients with 
ic malignancies currently receive
gal treatment
;Uso
high among these 5, so se cases of invasive as
by using the alternative strategy may 
the most from being given first-line treatment with L- 
AmB. However, the costs o f treating all such patients with L- 
AmB will be high; thus a comparative study of L-AmB and 
DC-AmB is still required to determine the feasibility of this
Prevalence of invasive aspergillosis (%)
Figure 2. One-way sensitivity analysis of the decision tree to deter­
mine the effect of the prevalence of invasive aspergillosis on the 
expected costs per patient. The prevalence of aspergillosis is varied 
in the sensitivity analysis which results in lines indicating the expected 
costs of each strategy. Where the lines of the strategies intersect 
(prevalence of 13%, given baseline test performance), this intersection 
defines a threshold point. If the prevalence of invasive aspergillosis 
is below the threshold, the conventional strategy is optimal; if this 
prevalence is above the threshold, then the alternative strategy is 
optimal. Baseline values for the sensitivity and specificity of ELISA 
in the alternative strategy are 100% and 94%, respectively. The worst 
case values, 67% for sensitivity and 84% for specificity, result in a 
threshold of 11.5%; in the best case these values are both 100%,
which results in a threshold o f  15.1%. ( - f i conventional strategy;
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specificity of the sandwich ELISA [21]. However, since Figure 3, Two-way sensitivity analysis of the decision tree to deter-
sequential tests and procedures are used in the alternative strat- 
to diagnose invasive aspergillosis, the impact o f a less 
sensitive and specific ELISA on the positive and negative pre-
mine fleet of the prevalence of invasive aspergillosis and the 
percentage of treated patients who received liposomal amphotericin 
B (L-AmB) in both strategies according to the expected costs per 
patient. As in figure 2, the results for the worst-casc and hest-case
dictive values of the strategy as a whole is likely to be negligi- values of sensitivity and specificity, as well as baseline values for 
ble. Nevertheless, the total costs per patient will increase con- sensitivity and specificity of ELLSA, are given. The curves indicate
siderably, especially if the specificity proves low. In addition the combinations of values for the prevalence of aspergillosis and 
percentage of patients treated with L-AmB for which the expected 
costs of the two strategies are equal. Any coordinate to the left of
o f the sandwich ELISA as a screening test for galactomannan the curves favors the conventional strategy, whereas any coordinate 
may also allow for the diagnosis to be made at an early stage to the right of the curves f avors the alternative strategy. There is an
to better selection of patients for i
, at least for some patients [7-9].
ventional strategy
current con-
expensive per patient than
2 strategy when patients were treated with
inverse relationship between prevalence of aspergillosis and percent­
age of patients treated with L-AmB. Thus, with our current preva- 
, we would only need to treat one of 20 treated patients with
alternative strategy would begin to pay for itselfL- 
(
i
«KCiMl
DC’-AmB. However, we sis retii ted to
baseline test performance;..........
test performance).
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approach by taking into account other important aspects such 
as outcome, adverse drug reactions, and costs.
In conclusion, we constructed a decision model to explore 
the feasibility of implementing an alternative strategy for diag­
nosing invasive aspergillosis in patients receiving treatment for 
hematologic malignancies. This model indicated that screening 
for galactomannan and using imaging techniques, as compared 
with the conventional strategy, will reduce the number of pa­
tients who require treatment and therefore may help to control 
the use of toxic or expensive antifungal agents. We are now 
planning to assess the feasibility and the cost-effectiveness of 
the alternative strategy in a prospective comparative trial in 
which patients with hematologic malignancies, who will be­
come neutropenic following cytotoxic therapy, will be random- 12- Poirot JL, Isnard F, Lesage S, Tabouret M. Detection of Aspergillus galac-
* *  _ -ft « i  . * . « w  «  a  r* 4
ized on admission to one or the other strategy, and all the 
relevant effects and costs, including those related to toxicity, 
will be registered.
8. Stynen D, Goris A, Sarfati J, Latge JP. A new sensitive sandwich enzyme-
linked immunosorbent assay to detect galactofuran in patients with 
invasive aspergillosis. J Clin Microbiol 1995;33:497..500.
9. Verweij PE, Stynen D, Rijs AJMM, de Pauw BE, Hoogkamp-Korstanje
JAA, Meis JFGM. Sandwich enzyme-linked immunosorbent assay com­
pared with Pastorex latex agglutination test for diagnosing invasive 
aspergillosis in immunocompromised patients. J Clin Microbiol 1995; 
33:1912-4.
10. Rohrlich P, Sarfati J, Mariani P, et al. Prospective sandwich enzyme-
linked immunosorbent assay for serum galactomannan: early predictive 
value and clinical use in invasive aspergillosis. Pediatr Infect Dis J
1996; 15:232-7.
11. Sulahian A, Tabouret M, Ribaud J, et al. Comparison of an enzyme immu­
noassay and latex agglutination test for detection of galactomannan in 
the diagnosis o f invasive aspergillosis, Eur J Clin Microbiol Infect Dis
1996; 15:139 -45.
References
1. Aisner J, Schimpff SC, Wiemik PH. Treatment of invasive aspergillosis:
relation of early diagnosis and treatment to response. Ann Intern Med
1977;86:539-43.
2. Denning DW. Treatment of invasive aspergillosis. J Infect 1994;28(suppl
I):25-33.
3. Goodman JL, Winston DJ, Greenfield RA, et a l  A controlled trial of
fluconazole to prevent fungal infections in patients undergoing bone 
marrow transplantation. N Engl J Med 1992;326:845-51.
4. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophy­
laxis of fungal infections in patients with acute leukemia: results o f a 
randomized, placebo-controlled, double blind, multicenter trial. Ann 
Intern Med 1993; 118:495-503.
5. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent
progress and future directions, Clin Infect Dis 1996;22(suppl 2):
S 133-44.
6 . Ng TTC, Denning DW. Liposomal amphotericin B (AmBisome) therapy
in invasive fungal infections: evaluation of United Kingdom compas­
sionate use data. Arch Intern Med 1995;155:1093-8.
7. Hiemenz JW, Lister J, Anaissie EJ, et ah Emergency-use amphotericin B
lipid complex (ABLC) in the treatment o f patients with aspergillosis: 
historical-control comparison with amphotericin B [abstract no 3383]. 
Blood 1995;86(suppl l ):849a.
tomannan in sera from hematological patients by ELISA [abstract no
3.21], Program and abstracts of the third meeting of the European Con­
federation of Medical Mycology (Lisbon). 1996.
13. Tabone MD, Vu Thien II, Latge JP, Landman-Parker J, Leverger G. Galac­
tomannan detection by sandwich enzyme-linked immunosorbent assay 
in the diagnosivs and follow-up of invasive aspergillosis [abstract no
3.22]. Program and abstracts o f the third meeting of the European 
Confederation o f Medical Mycology (Lisbon). 1996.
14. Kuhlman JE, Fishman EK, Siegelman SS. Invasive pulmonary aspergillo­
sis in acute leukemia: characteristic findings on CT, the CT halo sign 
and the role o f  CT in early diagnosis. Radiology 1985; 157:611 -4 .
15. Caillot D, Casasnovas O, Bernard A, et al. Improved management of
invasive pulmonary aspergillosis in neutropenic patients using early 
thoracic computed tomographic scan and surgery, J Clin Oncol 1997; 
15:139-47.
16. Rubin RH, Fischman AJ. Radionuclide imaging o f infection in the immu­
nocompromised host. Clin Infect Dis 1996;22:414-22.
17. Oyen WJG, Claessens RAMJ, Raemaekers JMM, de Pauw BE, van der
Meer JWM, Corstens FHM, Diagnosing infection in febrile granulocyto­
penic patients with indium-1 1 1 -labeled human immunoglobulin G. J 
Clin Oncol 1992;10:61-8.
18. McNeil BJ, Pauker SG. Decision analysis for public health: principles and
illustrations. Ann Rev Publ Health 1984;5:135-61.
19. Verweij PE, Donnelly JP, De Pauw BE, Meis JFGM. Prospects for the
early diagnosis of invasive aspergillosis in the immunocompromised 
patient. Rev Med Microbiol 1996; 7:105 13.
20. Groll AH, Shall PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner
K. Trends in the postmortem epidemiology of invasive fungal infections 
at a university hospital. J Infect 1996; 33:23..32,
21. Swanink CM, Meis JFGM, Rijs AJMM, Donnelly JP, Verweij PE, Speci­
ficity of a sandwich enzyme-linked immunosorbent assay for detecting 
Aspergillus galactomannan. J Clin Microbiol 1997; 35:257 60,
